The burden of respiratory syncytial virus in healthy term-born infants in Europe: a prospective birth cohort study

Joanne G Wildenbeest; Marie-Noelle Billard; Roy P Zuurbier; Koos Korsten; Annefleur C  Langedijk; Peter M  van de Ven; Matthew D Snape; Simon B Drysdale; Andrew J Pollard; Hannah Robinson; Terho Heikkinen; Steve Cunningham; Thomas  O'Neill; Bishoy Rizkalla; Ana Isabel Dacosta-Urbieta; Federico  Martinón-Torres; Marlies van Houten; Louis J Bont; RESCEU Investigators

doi:10.1016/S2213-2600(22)00414-3

The burden of respiratory syncytial virus in healthy term-born infants in Europe: a prospective birth cohort study

Joanne G Wildenbeest, Marie-Noelle Billard, Roy P Zuurbier, Koos Korsten, Annefleur C Langedijk, Peter M van de Ven, Matthew D Snape, Simon B Drysdale, Andrew J Pollard, Hannah Robinson, Terho Heikkinen, Steve Cunningham, Thomas O'Neill, Bishoy Rizkalla, Ana Isabel Dacosta-Urbieta, Federico Martinón-Torres, Marlies van Houten, Louis J Bont^*, RESCEU Investigators

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

Abstract / Description of output

Background
Respiratory syncytial virus (RSV) is a major cause of hospitalization in infants. The burden of RSV infection in healthy term infants has not yet been established. Accurate healthcare burden data in healthy infants are necessary to determine RSV immunization policy when RSV immunization becomes available.
Methods
We performed a multicenter prospective, observational birth cohort study in healthy term-born infants (≥37 weeks of gestation) in five sites located in different European countries to determine the healthcare burden of RSV. The incidence of RSV-associated hospitalizations in the first year of life was determined by parental questionnaires and hospital chart reviews. We performed active RSV surveillance in a nested cohort to determine the incidence of medically-attended RSV infection.
Findings
In total, 9154 infants born between July 2017 and April 2020 were followed during the first year of life and 993 participated in the nested active surveillance cohort. The incidence of RSV hospitalization in the total cohort was 1·8% (95% CI 1·6-2·1). There were eight pediatric intensive care unit admissions, corresponding to 5·5% of RSV hospitalizations and 0·09% of the total cohort. Incidences of RSV infection confirmed by any diagnostic assay and medically-attended RSV infection in the active surveillance cohort were 26·2% (95% CI 24·0-28·6) and 14·1% (95% CI 12·3-16·0), respectively.
Interpretation
RSV-associated acute respiratory infection causes substantial morbidity, leading to the hospitalization of one in every 56 healthy term-born infants in high-income settings. Immunization of pregnant women or healthy term-born infants during their first winter season could have a significant impact on the healthcare burden caused by RSV infections.

Original language	English
Journal	The Lancet Respiratory Medicine
Early online date	10 Nov 2022
DOIs	https://doi.org/10.1016/S2213-2600(22)00414-3
Publication status	E-pub ahead of print - 10 Nov 2022

Access to Document

10.1016/S2213-2600(22)00414-3

Manuscript_revision2_cleanAccepted author manuscript, 397 KBLicence: Creative Commons: Attribution (CC-BY)

REspiratory Syncytial virus Consortium in EUrope
Nair, H., Campbell, H. & Cunningham, S.
EU government bodies
1/01/17 → 31/12/21
Project: Research

Cite this

Wildenbeest, J. G., Billard, M.-N., Zuurbier, R. P., Korsten, K., Langedijk, A. C., van de Ven, P. M., Snape, M. D., Drysdale, S. B., Pollard, A. J., Robinson, H., Heikkinen, T., Cunningham, S., O'Neill, T., Rizkalla, B., Dacosta-Urbieta, A. I., Martinón-Torres, F., van Houten, M., Bont, L. J., & RESCEU Investigators (2022). The burden of respiratory syncytial virus in healthy term-born infants in Europe: a prospective birth cohort study. The Lancet Respiratory Medicine. Advance online publication. https://doi.org/10.1016/S2213-2600(22)00414-3

@article{fc3bee30e8024fd7abfb29c115a2b0b8,

title = "The burden of respiratory syncytial virus in healthy term-born infants in Europe: a prospective birth cohort study",

abstract = "BackgroundRespiratory syncytial virus (RSV) is a major cause of hospitalization in infants. The burden of RSV infection in healthy term infants has not yet been established. Accurate healthcare burden data in healthy infants are necessary to determine RSV immunization policy when RSV immunization becomes available. MethodsWe performed a multicenter prospective, observational birth cohort study in healthy term-born infants (≥37 weeks of gestation) in five sites located in different European countries to determine the healthcare burden of RSV. The incidence of RSV-associated hospitalizations in the first year of life was determined by parental questionnaires and hospital chart reviews. We performed active RSV surveillance in a nested cohort to determine the incidence of medically-attended RSV infection. FindingsIn total, 9154 infants born between July 2017 and April 2020 were followed during the first year of life and 993 participated in the nested active surveillance cohort. The incidence of RSV hospitalization in the total cohort was 1·8% (95% CI 1·6-2·1). There were eight pediatric intensive care unit admissions, corresponding to 5·5% of RSV hospitalizations and 0·09% of the total cohort. Incidences of RSV infection confirmed by any diagnostic assay and medically-attended RSV infection in the active surveillance cohort were 26·2% (95% CI 24·0-28·6) and 14·1% (95% CI 12·3-16·0), respectively. InterpretationRSV-associated acute respiratory infection causes substantial morbidity, leading to the hospitalization of one in every 56 healthy term-born infants in high-income settings. Immunization of pregnant women or healthy term-born infants during their first winter season could have a significant impact on the healthcare burden caused by RSV infections.",

author = "Wildenbeest, {Joanne G} and Marie-Noelle Billard and Zuurbier, {Roy P} and Koos Korsten and Langedijk, {Annefleur C} and {van de Ven}, {Peter M} and Snape, {Matthew D} and Drysdale, {Simon B} and Pollard, {Andrew J} and Hannah Robinson and Terho Heikkinen and Steve Cunningham and Thomas O'Neill and Bishoy Rizkalla and Dacosta-Urbieta, {Ana Isabel} and Federico Martin{\'o}n-Torres and {van Houten}, Marlies and Bont, {Louis J} and {RESCEU Investigators}",

year = "2022",

month = nov,

day = "10",

doi = "10.1016/S2213-2600(22)00414-3",

language = "English",

journal = "The Lancet Respiratory Medicine",

issn = "2213-2600",

publisher = "Elsevier",

}

Wildenbeest, JG, Billard, M-N, Zuurbier, RP, Korsten, K, Langedijk, AC, van de Ven, PM, Snape, MD, Drysdale, SB, Pollard, AJ, Robinson, H, Heikkinen, T, Cunningham, S, O'Neill, T, Rizkalla, B, Dacosta-Urbieta, AI, Martinón-Torres, F, van Houten, M, Bont, LJ & RESCEU Investigators 2022, 'The burden of respiratory syncytial virus in healthy term-born infants in Europe: a prospective birth cohort study', The Lancet Respiratory Medicine. https://doi.org/10.1016/S2213-2600(22)00414-3

TY - JOUR

T1 - The burden of respiratory syncytial virus in healthy term-born infants in Europe

T2 - a prospective birth cohort study

AU - Wildenbeest, Joanne G

AU - Billard, Marie-Noelle

AU - Zuurbier, Roy P

AU - Korsten, Koos

AU - Langedijk, Annefleur C

AU - van de Ven, Peter M

AU - Snape, Matthew D

AU - Drysdale, Simon B

AU - Pollard, Andrew J

AU - Robinson, Hannah

AU - Heikkinen, Terho

AU - Cunningham, Steve

AU - O'Neill, Thomas

AU - Rizkalla, Bishoy

AU - Dacosta-Urbieta, Ana Isabel

AU - Martinón-Torres, Federico

AU - van Houten, Marlies

AU - Bont, Louis J

AU - RESCEU Investigators

PY - 2022/11/10

Y1 - 2022/11/10

N2 - BackgroundRespiratory syncytial virus (RSV) is a major cause of hospitalization in infants. The burden of RSV infection in healthy term infants has not yet been established. Accurate healthcare burden data in healthy infants are necessary to determine RSV immunization policy when RSV immunization becomes available. MethodsWe performed a multicenter prospective, observational birth cohort study in healthy term-born infants (≥37 weeks of gestation) in five sites located in different European countries to determine the healthcare burden of RSV. The incidence of RSV-associated hospitalizations in the first year of life was determined by parental questionnaires and hospital chart reviews. We performed active RSV surveillance in a nested cohort to determine the incidence of medically-attended RSV infection. FindingsIn total, 9154 infants born between July 2017 and April 2020 were followed during the first year of life and 993 participated in the nested active surveillance cohort. The incidence of RSV hospitalization in the total cohort was 1·8% (95% CI 1·6-2·1). There were eight pediatric intensive care unit admissions, corresponding to 5·5% of RSV hospitalizations and 0·09% of the total cohort. Incidences of RSV infection confirmed by any diagnostic assay and medically-attended RSV infection in the active surveillance cohort were 26·2% (95% CI 24·0-28·6) and 14·1% (95% CI 12·3-16·0), respectively. InterpretationRSV-associated acute respiratory infection causes substantial morbidity, leading to the hospitalization of one in every 56 healthy term-born infants in high-income settings. Immunization of pregnant women or healthy term-born infants during their first winter season could have a significant impact on the healthcare burden caused by RSV infections.

AB - BackgroundRespiratory syncytial virus (RSV) is a major cause of hospitalization in infants. The burden of RSV infection in healthy term infants has not yet been established. Accurate healthcare burden data in healthy infants are necessary to determine RSV immunization policy when RSV immunization becomes available. MethodsWe performed a multicenter prospective, observational birth cohort study in healthy term-born infants (≥37 weeks of gestation) in five sites located in different European countries to determine the healthcare burden of RSV. The incidence of RSV-associated hospitalizations in the first year of life was determined by parental questionnaires and hospital chart reviews. We performed active RSV surveillance in a nested cohort to determine the incidence of medically-attended RSV infection. FindingsIn total, 9154 infants born between July 2017 and April 2020 were followed during the first year of life and 993 participated in the nested active surveillance cohort. The incidence of RSV hospitalization in the total cohort was 1·8% (95% CI 1·6-2·1). There were eight pediatric intensive care unit admissions, corresponding to 5·5% of RSV hospitalizations and 0·09% of the total cohort. Incidences of RSV infection confirmed by any diagnostic assay and medically-attended RSV infection in the active surveillance cohort were 26·2% (95% CI 24·0-28·6) and 14·1% (95% CI 12·3-16·0), respectively. InterpretationRSV-associated acute respiratory infection causes substantial morbidity, leading to the hospitalization of one in every 56 healthy term-born infants in high-income settings. Immunization of pregnant women or healthy term-born infants during their first winter season could have a significant impact on the healthcare burden caused by RSV infections.

U2 - 10.1016/S2213-2600(22)00414-3

DO - 10.1016/S2213-2600(22)00414-3

M3 - Article

SN - 2213-2600

JO - The Lancet Respiratory Medicine

JF - The Lancet Respiratory Medicine

ER -

The burden of respiratory syncytial virus in healthy term-born infants in Europe: a prospective birth cohort study

Abstract / Description of output

Access to Document

Fingerprint

Projects

REspiratory Syncytial virus Consortium in EUrope

Cite this